PHGE Fundamental Analysis - BIOMX INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to PHGE. PHGE was compared to 538 industry peers in the Biotechnology industry. While PHGE seems to be doing ok healthwise, there are quite some concerns on its profitability. PHGE is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

PHGE had negative earnings in the past year.

In the past year PHGE has reported a negative cash flow from operations.

In the past 5 years PHGE always reported negative net income.

In the past 5 years PHGE always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of PHGE (-48.80%) is comparable to the rest of the industry.

The Return On Equity of PHGE (-96.91%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-48.8%
ROE	-96.91%
ROIC	N/A

ROA(3y)-69.25%

ROA(5y)-59.4%

ROE(3y)-352.46%

ROE(5y)-237.19%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PHGE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

Compared to 1 year ago, PHGE has less shares outstanding

PHGE has more shares outstanding than it did 5 years ago.

PHGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -9.43, we must say that PHGE is in the distress zone and has some risk of bankruptcy.

PHGE's Altman-Z score of -9.43 is on the low side compared to the rest of the industry. PHGE is outperformed by 71.75% of its industry peers.

PHGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-9.43

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

PHGE has a Current Ratio of 2.66. This indicates that PHGE is financially healthy and has no problem in meeting its short term obligations.

PHGE has a Current ratio of 2.66. This is in the lower half of the industry: PHGE underperforms 68.03% of its industry peers.

A Quick Ratio of 2.66 indicates that PHGE has no problem at all paying its short term obligations.

PHGE has a worse Quick ratio (2.66) than 66.17% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.66
Quick Ratio	2.66

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for PHGE have decreased strongly by -60.04% in the last year.

EPS 1Y (TTM)-60.04%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%72.86%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

PHGE is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.74% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y25.64%

EPS Next 2Y20.83%

EPS Next 3Y11.95%

EPS Next 5Y6.74%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

PHGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHGE. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y20.83%

EPS Next 3Y11.95%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PHGE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOMX INC

NYSEARCA:PHGE (9/23/2025, 8:04:01 PM)

After market: 0.5288 0 (0%)

0.5288

-0.01 (-1.16%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-13 2025-08-13/bmo

Earnings (Next)11-12 2025-11-12/bmo

Inst Owners43.18%

Inst Owner Change-18.38%

Ins Owners1.48%

Ins Owner Change9.12%

Market Cap14.04M

Analysts82.5

Price Target15.81 (2889.79%)

Short Float %2.46%

Short Ratio0.08

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)20.96%

Min EPS beat(2)-0.76%

Max EPS beat(2)42.68%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-16.22%

PT rev (3m)-16.22%

EPS NQ rev (1m)15.79%

EPS NQ rev (3m)-540%

EPS NY rev (1m)0%

EPS NY rev (3m)-24.18%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.73
P/tB	1.97
EV/EBITDA	N/A

EPS(TTM)-0.73

EYN/A

EPS(NY)-1.41

Fwd EYN/A

FCF(TTM)-1.1

FCFYN/A

OCF(TTM)-1.1

OCFYN/A

SpS0

BVpS0.72

TBVpS0.27

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-48.8%
ROE	-96.91%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-69.25%

ROA(5y)-59.4%

ROE(3y)-352.46%

ROE(5y)-237.19%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.66
Quick Ratio	2.66
Altman-Z	-9.43

F-ScoreN/A

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)3.92%

Cap/Depr(5y)40.26%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-60.04%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%72.86%

EPS Next Y25.64%

EPS Next 2Y20.83%

EPS Next 3Y11.95%

EPS Next 5Y6.74%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-18.71%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-24.55%

EBIT Next 3Y-20.08%

EBIT Next 5Y-5.98%

FCF growth 1Y-34.01%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-34.22%

OCF growth 3YN/A

OCF growth 5YN/A

BIOMX INC (PHGE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens